Topics
Treatment, Screening / Early detection, Outcomes / Survival, Side effects / Toxicity, Prevention / Risk, Epidemiology
Modality
Imaging
Study type
Observational, Review / Meta-analysis
Abstract
The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including…
Authors
Buckman, M., Vasileva, A., Jedlicka, C., Vasilyev, M. +4
AI-generated summary
Cancer and Post-therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults with Down Syndrome reports: The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including age-related malignancies, and the impact of standard cancer treatments on cardiovascular health. We retrospectively reviewed medical records for age- and sex-matched patients [≥]15 years old with and without Down syndrome using the TriNetX platform to identify the prevalence of malignancies and explore cardiovascular outcomes after treatment with anthracyclines. This is a preprint and not peer reviewed.
This summary may be inaccurate. Verify with the primary paper.
Primary source: medRxiv (not peer reviewed).